--- title: "WALVAX \"Breaking the Circle\" Record: Vaccine Going Global 2.0 Combined with Synthetic Biology Track, Restructuring Growth Logic" type: "News" locale: "en" url: "https://longbridge.com/en/news/287043989.md" description: "WALVAX is accelerating its transformation, planning to reconstruct its growth logic through the internationalization of its self-developed products and the new track of biomanufacturing. It is expected that by 2025, the operating revenue will reach 2.418 billion yuan, with a net profit of 178 million yuan, a year-on-year increase of 25.03%. The company's overseas business revenue exceeds 522 million yuan, with significant growth, and it has promoted technology transfer in multiple countries, upgrading to the \"Going Global 2.0 Model,\" providing full industry chain cooperation services" datetime: "2026-05-20T09:54:07.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/287043989.md) - [en](https://longbridge.com/en/news/287043989.md) - [zh-HK](https://longbridge.com/zh-HK/news/287043989.md) --- # WALVAX "Breaking the Circle" Record: Vaccine Going Global 2.0 Combined with Synthetic Biology Track, Restructuring Growth Logic Against the backdrop of intensified competition in the domestic vaccine industry and the prominence of stock game, the established vaccine leader WALVAX (300142.SZ) is accelerating the removal of the label of "single vaccine manufacturer." The company's recently disclosed performance and strategic direction for 2025 show that it is clearly anchoring on two major directions: "internationalization of self-owned products" and "new track in biomanufacturing," attempting to build long-term competitive barriers through a dual drive of "prevention + health." In 2025, WALVAX achieved operating revenue of 2.418 billion yuan, with a net profit attributable to shareholders of the listed company of 178 million yuan, a year-on-year increase of 25.03%. Industry observers believe that compared to short-term financial data, WALVAX's acceleration in overseas markets and the substantial landing of new tracks such as synthetic biology better reflect its long-term value reconstruction path as a platform-based biopharmaceutical company. #### Going Global 2.0: From "Selling Products" to "Turnkey Projects" Internationalization has become the core incremental market for WALVAX's monetization of self-owned products. In 2025, the company's overseas business revenue exceeded 522 million yuan, a year-on-year increase of 37%, which far exceeds domestic business growth and has become an important stabilizer for performance. Currently, the company's products have been exported to 26 countries and regions, covering Southeast Asia, South Asia, Africa, Latin America, and other areas. Unlike the early stage of simple product trade exports, the company's current overseas model is upgrading to a multi-track parallel approach of "self-owned product registration supply + innovative product international clinical trials + technology transfer for localized production." Yang Hongwei, General Manager of International Marketing at WALVAX, pointed out in a recent research activity that the company has carved out a differentiated path for going global: relying on independent technology to achieve an upgrade from product export to technology transfer and localized production. The "Going Global 2.0 model" extends from finished product exports to raw liquid supply, technology transfer, repackaging production, and even full industry chain cooperation (factories, equipment, logistics, system co-construction), providing partners with "turnkey projects," packaging technology, equipment, factory design, and training services, adapting to the policy needs of various countries, and helping target countries establish independent vaccine industry capabilities. Currently, the company is advancing technology transfer in countries such as Morocco, Indonesia, Malaysia, Bangladesh, Mexico, and Egypt. In 2025, the bivalent HPV vaccine obtained import approval in Nepal, the 13-valent pneumococcal conjugate vaccine successfully entered the African and Middle Eastern markets (such as Jordan and Egypt), and the 23-valent pneumococcal vaccine officially supplied the Philippines' national immunization program. Yang Hongwei stated that after 16 years of internationalization, WALVAX has carved out a path for Chinese characteristic vaccine globalization and will continue to promote technology output and industrial landing, allowing Chinese vaccines, Chinese technology, and Chinese manufacturing to benefit the world. #### Synthetic Biology: "Dimensionality Reduction" Migration of Vaccine Industrialization Capability, Creating a Second Curve To break the cyclical nature of the single vaccine track, WALVAX is actively laying out its plans in the fields of synthetic biology and biomanufacturing, perfecting the industrial closed loop of "preventing diseases + big health." The company's Vice President Duan Qingtang introduced that WALVAX is leveraging over 20 years of industrialization advantages and core technology transformation capabilities accumulated in the vaccine field, migrating and applying them to the synthetic biomanufacturing sector, and constructing a research and development model that combines independent research and collaborative innovation. Currently, in the newly operational Anning synthetic biology base, a complete phototrophic biosynthesis technology system for extracting algal-derived natural astaxanthin is running in an orderly manner, achieving a natural astaxanthin content of 6% of the cell dry weight, which has reached a world-class level. The base "covers an area of 216 acres, with only 8 months from construction to production, and achieving sales revenue in 10 months, fully producing and selling." Next to the base, the "cell factory astaxanthin project" that is being laid out is also about to enter the industrialization stage. This is an upgraded version based on synthetic biology technology, aiming to significantly improve the biosynthesis efficiency of astaxanthin and greatly reduce production costs through the reconstruction of metabolic engineering and enzyme catalysis systems, expanding application scenarios. Duan Qingtang stated that the company has laid out a batch of innovative synthetic biology varieties (such as algal-derived fucoxanthin with effects like fat reduction and liver protection, as well as new quality proteins), and has built a ubiquitous synthetic biology innovation and pilot verification platform, bridging the critical intermediate links from the laboratory to the workshop, ultimately achieving large-scale production to supply the market. In February 2026, WALVAX also announced plans to invest 450 million yuan to jointly initiate the establishment of the "Yunnan Chuangwo Biological Industry Investment Fund" with Guotou Chuangyi and others, targeting a scale of 1 billion yuan. The investment direction focuses on synthetic biology, biomanufacturing, and biotechnology-related industries, aiming to integrate resources through the "industry + fund" model, reduce investment risks for single entities, and assist in the layout of WALVAX's synthetic biomanufacturing business. #### Technical Platform and Full-Chain Layout: Extensions of mRNA and Microecology Supporting WALVAX's overseas expansion and new track development is its self-developed technology platform accumulated over many years. The company's Chairman Li Yunchun introduced that WALVAX has mastered four core technology platforms, including bacterial vaccine technology platform, recombinant protein vaccine technology platform, mRNA vaccine technology platform, and viral vaccine technology platform. With the support of these four platforms, WALVAX has already launched 8 approved products and ranks among the top ten vaccine manufacturers globally. Among them, the mRNA innovative technology platform is a representative achievement of fully controllable self-sufficiency across the entire chain. Li Yunchun stated that the breakthrough of this platform means establishing a technological reserve and capability for rapid response to future emerging infectious diseases. Based on this, the company is laying out plans to utilize the established mRNA technology platform to expand into fields such as tumor vaccines, protein replacement drugs, and cell therapy. Lin Jinzhong, a tenured professor at Fudan University's School of Life Sciences, pointed out that the mRNA platform possesses three core capabilities: speed, programmability and reusability, and instantaneous expression, leading the next generation of biomedicine revolution, with future focuses on expanding delivery range and upgrading to a "drug platform." Lin Jinchong stated: "In the future, we will focus on three directions: first, breaking through the bottleneck of extrahepatic delivery, allowing mRNA to accurately, safely, and repeatedly reach more tissues such as muscles, lungs, and lymph nodes; second, expanding mRNA from preventive vaccines to therapeutic drugs, covering fields such as tumors, rare diseases, and chronic diseases; third, solidifying a self-controllable underlying technology system, including humanized in vitro translation systems and AI-driven sequence and delivery design. China does not have to be just a follower; on the main track of next-generation nucleic acid drugs, we have the conditions to move from following and running in parallel to leading. In the past five years, we have proven that mRNA can be used for vaccines; in the next five years, we want mRNA to truly become a new class of drugs." In the field of intestinal microecology, WALVAX collaborates with Professor Zhao Liping from Shanghai Jiao Tong University to jointly build a "core microbial therapy" technology platform, aiming to achieve "multi-disease co-treatment" for chronic metabolic diseases such as obesity and type 2 diabetes by regulating the balance of "keystone functional group" bacteria in the intestine. Currently, a full-chain industrial layout for microbial testing, nutritional preparations, and microbial transplantation has been achieved. The global biopharmaceutical industry is undergoing profound changes, and the company continues to consolidate its vaccine core business while proactively laying out new tracks such as intestinal microecology and biomanufacturing, striving to transition from a "leading vaccine enterprise" to an "innovative bio-economy leader." Li Yunchun discussed the layout for the next five years, stating: "We hope to further consolidate vaccines as a cornerstone business while creating a combination of vaccines and biomanufacturing industries, developing a biomanufacturing industry based on synthetic biology technology, in response to the national layout under the 'biomanufacturing' and 'Healthy China' strategies. In the next five years, we expect to establish a full-chain industrial layout of 'vaccines + innovative drugs + biomanufacturing + nutritional health.'" "The core of long-term growth for vaccine companies lies in the continuous launch of self-developed blockbuster pipelines and the ability to realize them globally," pointed out a pharmaceutical industry analyst. WALVAX breaks through revenue growth limits through self-developed overseas layouts, effectively hedging performance fluctuations of single categories through new synthetic biology tracks, and the value of the full industrial chain platform will gradually be released in the concentrated production of self-developed products and the scale expansion of new tracks. As overseas registration and supply chain systems become increasingly mature, the share of self-developed vaccines in emerging markets is rising, and the production capacity of synthetic biomanufacturing projects is being released with extended added value. WALVAX's diversified growth pattern of "prevention + treatment/health" and "domestic + international" is gradually entering the verification and realization stage ### Related Stocks - [300142.CN](https://longbridge.com/en/quote/300142.CN.md) ## Related News & Research - [The best biotech stocks to buy in 2026](https://longbridge.com/en/news/290106847.md) - [20:00 ETLOTTE Biologics Completes Construction of Songdo Bio Campus Plant 1 and Obtains Approval for Use](https://longbridge.com/en/news/290362832.md) - [5 Biotech Stocks That Delivered Triple-Digit Gains - SYRE Up 400%, BFLY Up 300% & More](https://longbridge.com/en/news/290324525.md) - [Biovica says new Phase III data show DiviTum TKa captures treatment-specific biological response in metastatic breast cancer](https://longbridge.com/en/news/290005590.md) - [Changzhou Investment-backed Tianchen Biomed lists in Hong Kong, raises HKD 1.36 billion](https://longbridge.com/en/news/290381537.md)